Analysis of clinical characteristics and influencing factors of patients with postmenopausal osteoporosis combined with dyslipidemia.
10.12200/j.issn.1003-0034.20250217
- Author:
Rong XIE
1
;
Li-Guo ZHU
2
;
Zi-Kai JIN
2
;
Tian-Xiao FENG
3
;
Ke ZHAO
2
;
Da WANG
2
;
Ling-Hui LI
2
;
Xu WEI
2
Author Information
1. Beijing University of Chinese Medicine, Beijing 100029, China; Wangjing Hospital, China Academy of Traditional Chinese Medicine, Beijing 100102, China.
2. Wangjing Hospital, China Academy of Traditional Chinese Medicine, Beijing 100102, China.
3. Beijing University of Chinese Medicine, Beijing 100029, China.
- Publication Type:Journal Article
- Keywords:
Co-morbidities;
Dyslipidemia;
Influencing factors;
Postmenopausal osteoporosis
- MeSH:
Humans;
Dyslipidemias/epidemiology*;
Female;
Middle Aged;
Osteoporosis, Postmenopausal/metabolism*;
Aged;
Cross-Sectional Studies;
Risk Factors;
Bone Density
- From:
China Journal of Orthopaedics and Traumatology
2025;38(5):487-493
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the co-morbid influencing factors of postmenopausal osteoporosis(PMOP) and dyslipidemia, and to provide evidence-based basis for clinical co-morbidity management.
METHODS:Based on the 2017 to 2018 Beijing community cross-sectional survey data, PMOP patients were included and divided into the dyslipidemia group and the uncomplicated dyslipidemia group according to whether they were comorbid with dyslipidemia. Demographic characteristics, living habits and disease history were collected through questionnaires, and bone mineral density and bone metabolism biomarkers (osteocalcin, blood calcium, serum typeⅠprocollagen N-terminal prepeptide, etc.) were detected on site. Co-morbidity risk factors were analyzed using binary logistic regression.
RESULTS:Three hundred and twenty patients with PMOP were included, including the comorbid group (75 patients) and the uncomplicated group (245 patients). The results showed that history of cardiovascular disease [OR=1.801, 95%CI(1.003, 3.236), P=0.049], history of cerebrovascular disease [OR=2.923, 95%CI(1.460, 5.854), P=0.002], frying and cooking methods[OR=5.388, 95%CI(1.632, 17.793), P=0.006], OST results[OR=0.910, 95%CI(0.843, 0.983), P=0.016], and blood Ca results [OR=60.249, 95%CI(1.862, 1 949.926), P=0.021] were the influencing factors of PMOP complicated with dyslipidemia.
CONCLUSION:Focus should be placed on the influencing factors of PMOP and dyslipidemia co-morbidities, with emphasis on multidimensional assessment, combining lifestyle interventions with bone metabolism marker monitoring to optimize co-morbidity management.
